In a phase I study of HER2‐directed CAR T cells in advanced pancreatic cancers [18], measured outcomes include off‐tumor toxicities of HER2, partial response rate, achievement of stable disease, and therapeutic levels of HER2 CAR T cells in vivo. The gene discussed is ERBB2; the disease is neoplasm.